Boucly Athénaïs, O'Connell Caroline, Savale Laurent, O'Callaghan Dermot S, Jaïs Xavier, Montani David, Humbert Marc, Simonneau Gérald, Sitbon Olivier
AP-HP, hôpital Bicêtre, centre de référence de l'hypertension pulmonaire sévère, service de pneumologie et soins intensifs, DHU TORINO, 94275 Le Kremlin-Bicêtre, France; Université Paris-Sud, faculté de médecine, 94270 Le Kremlin-Bicêtre, France; Inserm U999, HTAP : « physiopathologie et innovation thérapeutique », 92350 Le Plessis-Robinson, France.
Mater Misericordiae University Hospital, Department of Respiratory Medicine, Dublin, Irlande.
Presse Med. 2016 Jan;45(1):20-8. doi: 10.1016/j.lpm.2015.10.001. Epub 2015 Nov 4.
Intravenous prostacyclins are a valuable treatment for patients with severe pulmonary arterial hypertension, leading to improved exercise capacity, haemodynamics, quality of life and survival. Unfortunately, due to the short half-life of these drugs, they need to be administered continuously through central venous catheters. Despite aseptic technique, regular dressing changes, tunneled central venous catheters and patient education, patients are exposed to central venous catheter associated infections. These infections cause significant morbidity and mortality. The clinical presentation, microbiology, consequences and management of these central venous catheter associated infections in pulmonary arterial hypertension patients treated with intravenous prostacyclins are discussed.
静脉注射前列环素对重度肺动脉高压患者是一种有效的治疗方法，可提高运动能力、改善血流动力学、提高生活质量并延长生存期。不幸的是，由于这些药物半衰期短，需要通过中心静脉导管持续给药。尽管采用了无菌技术、定期更换敷料、使用隧道式中心静脉导管并对患者进行了教育，但患者仍有发生中心静脉导管相关感染的风险。这些感染会导致严重的发病和死亡。本文讨论了接受静脉注射前列环素治疗的肺动脉高压患者发生这些中心静脉导管相关感染的临床表现、微生物学、后果及处理方法。
